DAEWON PHARMACEUTICAL CO.,LTD
Financials
Valuation Metrics
DAEWON PHARMACEUTICAL CO.,LTD's Market Cap is ₩1770B. At end of 2025 it was ₩2680B. Ranked #920 of 2,421 in KR market (top 38%), #480 of 781 on KOSPI (top 61%), #101 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 44%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 176.95B KRW | KR#920/2,421 Sec#101/231 |
| Revenue | 614.64B KRW | KR#551/2,421 Sec#23/231 |
| Net Income | 288.5M KRW | KR#1,528/2,421 Sec#106/231 |
| Total Assets | 573.33B KRW | KR#710/2,421 Sec#39/231 |
| Net Assets | 275.73B KRW | KR#759/2,421 Sec#50/231 |
| Employees | 1,332 | KR#197/2,421 Sec#11/231 |
| Value | ||
| P/E | 613.45x | KR#1,544/2,421 Sec#107/231 |
| P/B | 0.64x | KR#1,040/2,421 Sec#55/231 |
| P/S | 0.29x | KR#570/2,421 Sec#15/231 |
| FCF Yield | 7.07% | KR#724/2,421 Sec#37/231 |
| Profitability | ||
| ROE | 0.10% | KR#1,538/2,421 Sec#106/231 |
| ROA | 0.05% | KR#1,539/2,421 Sec#106/231 |
| Op. Margin | -0.02% | KR#1,603/2,421 Sec#112/231 |
| Revenue Growth | 1.83% | KR#1,402/2,421 Sec#138/231 |
| Financial Health | ||
| Debt Ratio | 107.93% | KR#1,624/2,421 Sec#186/231 |
| Total Debt | 368.87B KRW | KR#362/2,421 Sec#17/231 |
| FCF | 12.51B KRW | KR#655/2,421 Sec#38/231 |
| Cash | 23.73B KRW | KR#1,143/2,421 Sec#77/231 |
| Current Ratio | 1.12x | KR#1,583/2,421 Sec#160/231 |
| Dividend | ||
| Div. Yield | 3.19% | KR#602/2,421 Sec#24/231 |
| Div. Growth | -16.67% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | -40.63% | KR#1,845/2,421 Sec#156/231 |
| 1M Return | 1.68% | KR#1,060/2,421 Sec#80/231 |
| From 52W High | -42.28% | KR#1,021/2,421 Sec#72/231 |
| 1Y MDD | -46.17% | KR#819/2,421 Sec#66/231 |
| Trading | ||
| Volume | 10,386 shares | KR#1,898/2,421 Sec#183/231 |
| Trading Value | 81.9M KRW | KR#1,645/2,421 Sec#164/231 |
| Foreign Own. | 13.12% | KR#370/2,421 Sec#26/231 |
| Per Share | ||
| EPS | 13 KRW | KR#1,542/2,421 Sec#107/231 |
| BPS | 12,294 KRW | KR#835/2,421 Sec#58/231 |
Company Info
Daewon Pharmaceutical, incorporated in 1961, currently holds 11 subsidiaries, with Beijing Skinlala's liquidation expected by 2025. The company's core business involves manufacturing and selling pharmaceuticals, cosmetics, and health functional foods, supplying new drugs, incrementally modified drugs, and generic drugs to domestic medical institutions. Leveraging excellent GMP-certified production facilities and specialized products, Daewon Pharmaceutical engages in CMO business, exports finished pharmaceuticals and medical devices, and operates a health functional food business focused on Jangdaewon. The company is headquartered in Seongdong-gu, Seoul.